openPR Logo
Press release

Herpes Zoster (Shingles) Market Report Forecasts Impressive Growth by 2024

05-26-2017 03:42 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Herpes Zoster also known as zoster or shingles is a painful contagious viral disease which is characterized by blisters in limited area and painful skin rashes. These blisters full of liquid and pus appear on either side of the body or face, left or right in a single stripe. This disease is caused by varicella zoster virus which develops short lived or acute illness named as chickenpox that is usually seen in young adults and children. Patients who never got chickenpox cannot get shingles. The onset of the infection caused by this virus is also seen years after the episode of chicken pox has been resolved as at that time varicella virus is not eliminated completely from the body. Though shingles can develop at any age, people who had chickenpox before the age of 1 and people who are above the age of 60 are more likely to develop this condition. Senior citizens (aged 60 and above). People whose immune system is weakened by medications or disease are also likely to develop this condition. Diagnosis usually depends on the signs and synonyms of the person. After the resolution of chicken pox herpes virus remains in latent phase in nerve cell bodies or in non-neuronal satellite cells of the cranial nerve, autonomic ganglia or dorsal root. However, after decades the virus is again activated due to weakening of immune system that might occur owing to fever, aging or stress. The virus may spread from one nerve ganglia to another of an affected skin area. Headache, fever, nausea and malaise are the earlier symptoms of herpes zoster which may also result in incorrect diagnosis. However, these symptoms may be followed by itching, burning pain, oversensitivity or numbness. Over this area rash or band strip is developed which turns into blisters few days later. This blister is filled with fluid that usually takes 2 weeks to 4 weeks to recover.

Browse through Herpes Zoster (Shingles) Market report to know what factors will shape the market by 2024: http://www.transparencymarketresearch.com/herpes-zoster-market.html

Shingles is most common in old age people as compared to young age generation because they have weak immune system that might develop due to fever, stress, certain medications or injury. Similarly, people undergoing chemotherapy or radiation therapy or taking medications such as steroids that weaken immune system are more prone to be victim of shingles infection. According to the Centers for Disease Control and prevention (CDC) in the United States every year more than 1 million cases of herpes zoster are estimated. Similarly, approximately 1 out of every 3 people in the United States develops herpes zoster once in their lifetime. Thus, for the diagnosis of herpes zoster laoboratory tests are performed which majorly detects VZV-specific IgM antibody in the blood. This antibody occurs in the blood stream only during the time of chicken pox or herpes zoster. After the diagnosis of the disease certain medications also prescribed for the treatment that include antiviral medications (acyclovir, famciclovir and valcyclovir), narcotic medications, anti-inflammatory medications, antihistamines (Benadryl), anticonvulsants or zostrix cream and others.

Furthermore, for the prevention of viral infection vaccines are prescribed to prevent an individual from developing severe shingles complications or symptoms. Zostavax is a live vaccine that is marketed for VZV. These vaccines are recommended by the Advisory Committee on Immunization Practices (ACIP), U.S. to reduce the risk of shingles and its associated pain in people aged over 60 years. In England annual incidence of shingles for those aged 70 years to 79 years is anticipated to be around 800 to 900 cases per 100,000 people.

Geographically, North America is the leading geography followed by the European market. Market growth of these regions is accounted due to presence of large base of population suffering from shingles. Asia-Pacific and Rest of the world region in the future are expected to emerge as fastest growing economies in this market.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Herpes Zoster (Shingles) Market by 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14999

Herpes Zoster Market Key Players

Major players that are involved in the development of therapeutics against shingles include Astellas Pharma, Inc. GlaxoSmithKline PLC, Foamix Ltd., Epiphany Biosciences and Merck & Co.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Herpes Zoster (Shingles) Market Report Forecasts Impressive Growth by 2024 here

News-ID: 552691 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Herpes

Global Herpes Labialis (Oral Herpes) Drugs Market Future Analysis Report 2018-20 …
This report studies the global market size of Herpes Labialis (Oral Herpes) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Herpes Labialis (Oral Herpes) Drugs in these regions. This research report categorizes the global Herpes Labialis (Oral Herpes) Drugs market by players/brands, region, type and application. This report also studies the global market status, competition
Drugs for Herpes Labialis (Oral Herpes) Market: GSK, Novartis, Teva, Mylan
HTF MI recently broadcasted a new study in its database that highlights the in-depth market analysis with future prospects of Drugs for Herpes Labialis (Oral Herpes) market. The study covers significant data which makes the research document a handy resource for managers, industry executives and other key people get ready-to-access and self-analyzed study along with graphs and tables to help understand market trends, drivers and market challenges. Some of the
Global Herpes Labialis (Oral Herpes) Clinical Trials Assessment & Evaluation, H2 …
Market Research Hub (MRH) has include a fresh report to its database titled “Herpes Labialis (Oral Herpes) Global Clinical Trials Review, H2, 2017”, an overview of trial numbers along with the average enrollment in major countries conducted across the globe. Furthermore, the report also presents prominent drugs for in-progress trials based on the count of ongoing trails. Request Free Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1350157 Oral herpes is a type of infection which occurs on
Worldwide Herpes Labialis (Oral Herpes) Drugs Information and Market Trend Resea …
Global Herpes Labialis (Oral Herpes) Drugs Market Research Report 2017"" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- In this report, the global Herpes Labialis (Oral Herpes) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented
Global Drugs For Herpes Labialis (Oral Herpes) Market 2017 - Teva, Mylan, Cadila …
Apex Market Reports, recently published a detailed market research study focused on the "Drugs For Herpes Labialis (Oral Herpes) Market" across the global, regional and country level. The report provides 360° analysis of "Drugs For Herpes Labialis (Oral Herpes) Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Drugs For
Drugs for Herpes Labialis (Oral Herpes) Market 2017- Teva, Apotex, Cadila, Mylan …
Apex Research, recently published a detailed market research study focused on the "Drugs for Herpes Labialis (Oral Herpes) Market" across the global, regional and country level. The report provides 360° analysis of "Drugs for Herpes Labialis (Oral Herpes) Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Drugs for Herpes Labialis (Oral